Therapeutic potential of NOX inhibitors in neuropsychiatric disorders

Psychopharmacology (Berl). 2023 Sep;240(9):1825-1840. doi: 10.1007/s00213-023-06424-5. Epub 2023 Jul 28.

Abstract

Rationale: Neuropsychiatric disorders encompass a broad category of medical conditions that include both neurology as well as psychiatry such as major depressive disorder, autism spectrum disorder, bipolar disorder, schizophrenia as well as psychosis.

Objective: NADPH-oxidase (NOX), which is the free radical generator, plays a substantial part in oxidative stress in neuropsychiatric disorders. It is thought that elevated oxidative stress as well as neuroinflammation plays a part in the emergence of neuropsychiatric disorders. Including two linked with membranes and four with subunits of cytosol, NOX is a complex of multiple subunits. NOX has been linked to a significant source of reactive oxygen species in the brain. NOX has been shown to control memory processing and neural signaling. However, excessive NOX production has been linked to cardiovascular disorders, CNS degeneration, and neurotoxicity. The increase in NOX leads to the progression of neuropsychiatric disorders.

Result: Our review mainly emphasized the characteristics of NOX and its various mechanisms, the modulation of NOX in various neuropsychiatric disorders, and various studies supporting the fact that NOX might be the potential therapeutic target for neuropsychiatric disorders.

Conclusion: Here, we summarizes various pharmacological studies involving NOX inhibitors in neuropsychiatric disorders.

Keywords: Autism spectrum disorder; Bipolar disorder; Major depressive disorder; NOX; Neuropsychiatric; Oxidative stress; Psychosis; Schizophrenia.

Publication types

  • Review

MeSH terms

  • Autism Spectrum Disorder*
  • Depressive Disorder, Major* / drug therapy
  • Humans
  • NADPH Oxidases / metabolism
  • Oxidative Stress
  • Reactive Oxygen Species

Substances

  • NADPH Oxidases
  • Reactive Oxygen Species